Background. This phase 3b randomized, open-label study evaluated the immunogenicity and safety of coadministration of a hepatitis A and/or B vaccine with a quadrivalent oligosaccharide meningococcal CRM 197 -conjugate vaccine (MenACWY-CRM), in the context of an accelerated hepatitis A and/or B immunization schedule. Methods. A total of 252 healthy adult subjects were randomized to three groups to receive hepatitis A/B only (HepA/B), hepatitis A/B coadministered with MenACWY-CRM (HepA/B+MenACWY-CRM), or MenACWY-CRM only (MenACWY-CRM). Hepatitis A and/or B vaccination was administered in the form of a single booster dose or a primary three-dose series, depending on the hepatitis A and/or B vaccination history of subjects. Antibody responses to hepatitis A/B vaccination were assessed 1 month following the last hepatitis A and/or B dose. Serum bactericidal activity with human complement (hSBA) against meningococcal serogroups A, C, W-135, and Y was assessed 1 month post-MenACWY-CRM vaccination. Safety was monitored throughout the study. Results. At 1 month following the final hepatitis A and/or B vaccination, concomitant administration of hepatitis A/B and MenACWY-CRM was non-inferior to administration of hepatitis A/B alone in terms of geometric mean concentrations of antibodies against the hepatitis A and B antigens. One month post-MenACWY-CRM vaccination, the percentages of subjects achieving hSBA titers ≥8 for serogroups A, C, W-135, and Y in the HepA/B+MenACWY-CRM group (76, 87, 99, and 94%, respectively) were comparable to those in the MenACWY-CRM group (67, 82, 96, and 88%, respectively). The percentages of subjects reporting adverse events (AEs) were similar across study groups and a majority of the reported AEs were mild to moderate in nature. There were no study vaccine-related serious AEs. Conclusions. MenACWY-CRM can be administered concomitantly with a hepatitis A and/or B vaccine in the context of an accelerated hepatitis A and/or B immunization schedule without increasing safety concerns or compromising the immune responses to any of the vaccine antigens. [NCT01453348] 
I
nfection with Neisseria meningitidis is a leading cause of bacterial meningitis globally, and is associated with rapid onset of disease and significant fatality rates (∼10%). 1 Even with antibiotic treatment, as many as 19% of survivors of invasive meningococcal disease and young adults. 2 Travel to areas of high endemicity for meningococcal disease, or where there is an outbreak, is considered a risk factor associated with developing IMD. [5] [6] [7] Among travelers that contract meningococcal disease while abroad, transmission to close contacts upon their return has been reported. 8, 9 Most cases of IMD are attributed to infection by one of five immunologically distinct serogroups (A, B, C, W-135, and Y), with the relative distribution of these serogroups varying by geographic region and over time. Given the dynamic nature of meningococcal epidemiology, the best strategy to prevent IMD is vaccination with broadly protective vaccines. Currently, three glycoconjugate meningococcal vaccines against serogroups A, C, W-135, and Y are licensed for use in various countries. [10] [11] [12] MenACWY-CRM (Menveo ® , Novartis Vaccines, Siena, Italy) is a licensed quadrivalent oligosaccharide conjugate vaccine containing CRM 197 , a naturally occurring non-toxic mutant of the diphtheria toxin, as the carrier protein. 12 Results from phase 2 and phase 3 clinical studies demonstrate that MenACWY-CRM is immunogenic and well tolerated across all age groups starting at 2 months of age. [13] [14] [15] In addition, the results of clinical trials that evaluated concomitant administration of MenACWY-CRM with routine vaccines demonstrated that MenACWY-CRM did not increase safety concerns nor significantly interfered with immune responses to coadministered vaccines. [16] [17] [18] [19] Vaccination with a quadrivalent meningococcal conjugate vaccine is recommended for individuals traveling to areas where meningococcal disease is hyper-endemic or where there is an outbreak, including parts of Africa and Asia. 3, 6 Individuals traveling to these regions are also at risk for contracting acute viral hepatitis, [20] [21] [22] with hepatitis A and B considered to be among the more commonly acquired vaccine-preventable diseases in international travelers. 23 While hepatitis A infections can be severe enough to necessitate hospitalization, the overall case fatality rates are low. 22 In contrast, more than half a million individuals die every year worldwide from acute hepatitis B or chronic conditions associated with this infection. 24 Both types of hepatitis can be efficiently prevented through vaccination with relevant licensed monovalent or combined hepatitis A/B vaccines. [25] [26] [27] Currently, the World Health Organization recommends vaccination against these viruses for all non-immune individuals traveling to areas with moderate to high hepatitis A and/or B endemicity. 20 While the standard immunization schedule for hepatitis A and/or B vaccines includes three doses administered within a 6-month period, when necessary, such as imminent international travel plans, an accelerated three-dose administration schedule (days 0, 7, and 21-30, followed by a booster at 12 months) is available and has been demonstrated to be effective. 28, 29 Given the overlap of regions that show a moderate to high risk for meningococcal disease, as well as for hepatitis A and/or B diseases, the option to coadminister a quadrivalent meningococcal conjugate vaccine with a hepatitis A and/or B vaccine would simplify pre-travel immunization schedules among individuals traveling to such regions; however, potential interactions between concomitantly administered vaccines necessitates clinical evaluation. The present study was designed to assess if coadministration of MenACWY-CRM with a hepatitis A and/or B vaccine has an impact on the safety and/or immunogenicity of hepatitis A and/or B vaccination in healthy adults, in the context of an accelerated hepatitis A and/or B immunization schedule.
Materials and Methods
This phase 3b, open-label, randomized, multicenter study was conducted at four sites in Germany between October 2011 and January 2012 (Clinicaltrials.gov identifier NCT01453348). This study was undertaken in accordance with the International Conference on Harmonization Guidelines for Good Clinical Practice, with applicable local regulations (including European Directive 2001/20/EC), and with the ethical principles of the Declaration of Helsinki. The protocol was approved by the local Independent Ethics Committees prior to subject enrollment and written informed consent was obtained from all subjects.
The primary objective of the clinical study was to assess the non-inferiority of immune responses to hepatitis A and/or B vaccines given according to hepatitis vaccination history when coadministered with MenACWY-CRM, as compared to responses to hepatitis A and/or B vaccines administered alone, as measured by geometric mean concentrations (GMCs) of antibodies against hepatitis A and B antigens 28 days after a booster dose or the primary series.
Subjects
Eligible study participants were healthy male and female adults aged 18 to 64 years who had provided informed consent and, in the case of female subjects, had a negative urine pregnancy test. Individuals were excluded from enrollment if they had a previous personal history of infection with N. meningitidis, hepatitis A virus (HAV), or hepatitis B virus; previous immunization with any meningococcal vaccine; previous immunization with any hepatitis A and/or B vaccine within the past 5 years; previous receipt of any investigational agents or vaccines within 30 days prior to enrollment or intent to receive an investigational agent or vaccine prior to completion of the study; receipt of a licensed live or inactive vaccine within 30 or 15 days, respectively, prior to enrollment or intent to receive a licensed vaccine prior to completion of the study. Other exclusion criteria were: a significant acute infection within 7 days prior to enrollment or a fever within 3 days prior to enrollment; any serious acute, chronic, or progressive disease; epilepsy or a history of Guillain-Barré syndrome; a history of anaphylaxis, serious vaccine † On day 1 all subjects in the HepA/B and HepA/B + MenACWY-CRM groups received one dose of the combined hepatitis A/B vaccine. Depending on their vaccination history, this immunization was in the form of a booster dose or as a first dose of a three-dose primary series for hepatitis A and/or B. # One subject in the HepA/B group, who received the second dose of hepatitis A and/or B vaccine, did not receive the third dose nor provided a blood sample on days 29 and 57, due to the receipt of an excluded concomitant vaccine.
reactions or known allergy to any vaccine components; impairment of the immune system by any cause; or bleeding diathesis. Female subjects that were breastfeeding were also excluded. . While the standard adult dosage of Havrix is 1440 EU, the 720 EU dosage was used in this trial to ensure that subjects who received either the monovalent hepatitis A vaccine or the combined hepatitis A/B vaccine were vaccinated with the same hepatitis A antigen content, thus permitting comparability across the study groups. All hepatitis vaccines were each supplied as a sterile solution adsorbed on aluminum. The MenACWY-CRM vaccine, administered at 0.5 mL dose, was prepared by extemporaneous mixing of the lyophilized MenA-CRM component with the liquid MenCWY-CRM component just prior to injection. All vaccines were to be administered by intramuscular injection in the deltoid region of the non-dominant arm.
Vaccines and Vaccinations
The schedule of vaccinations and blood sample collections is described in Figure 1 . A total of 252 healthy adults were randomized in a ratio of 1:1:1 into three groups to receive the following vaccines on day 1: one dose of the combined hepatitis A/B vaccine (HepA/B group, n = 84), concomitant administration of one dose of the combined hepatitis A/B vaccine with one dose of MenACWY-CRM (HepA/B + MenACWY-CRM group, n = 84), or one dose of MenACWY-CRM (MenACWY-CRM group, n = 84). For the HepA/B and HepA/B + MenACWY-CRM groups, the combined hepatitis A/B vaccination on day 1 was in the form of either a booster or a primary dose, depending on the hepatitis A and/or B vaccination history of the subjects. Those subjects who were previously vaccinated against hepatitis A and B did not receive any additional vaccinations after the day 1 booster dose. For those subjects receiving a primary series, two additional doses of a hepatitis A and/or B vaccine were administered on days 8 and 29, in accordance with an accelerated immunization schedule, as follows: individuals who *Per the study criterion, subjects with a hepatitis A and/or B vaccination history must have received these immunizations more than 5 years prior to study entry.
were naive to any hepatitis A/B vaccination at enrollment received two additional doses of the combined hepatitis A/B vaccine, whereas individuals who were previously vaccinated with one of the monovalent vaccines received two subsequent doses of a hepatitis A or B monovalent vaccine, as appropriate depending on their pre-vaccination status.
Immunological Evaluation
Blood samples (20 mL) for serological evaluations were drawn on days 1 and 29 (for subjects who received a booster dose on day 1) or on day 57 (for subjects who received the primary series), as detailed in Figure 1 . Antibody responses to the hepatitis A and/or B vaccine were measured by ELISA and expressed as GMCs of anti-hepatitis A virus antigen (anti-HAV) antibodies or anti-hepatitis B surface antigen (anti-HBsAg) antibodies, as well as by the percentage of subjects with antibody concentrations considered to be protective for anti-HAV or anti-HBsAg antibodies (≥20 or ≥ 10 mIU/mL, respectively). All serological analyses for the hepatitis A and/or B vaccine responses were conducted at PPD Vaccines and Biologics Laboratory in Wayne, Pennsylvania, by laboratory staff who were blinded to both vaccine group assignment and study visit. Antibody responses to MenACWY-CRM were assessed by serum bactericidal assay with human complement (hSBA) against meningococcal serogroups A, C, W-135, and Y and expressed as the percentage of subjects with a seroresponse, the percentage of subjects with hSBA titers ≥8, and hSBA geometric mean titers (GMTs). 30 Seroresponse was defined by an increase from pre-vaccination hSBA titers <4 to post-vaccination hSBA titers ≥8, or at least a fourfold increase in hSBA titers for those subjects with pre-vaccination titers ≥4. All serological analyses for MenACWY-CRM were carried out at the Novartis Vaccines Clinical Serology Laboratory in Marburg, Germany, by laboratory staff who were blinded to both vaccine group assignment and study visit.
Safety Evaluations
Subjects were observed for 30 minutes after each vaccination for any immediate reactions. Safety was assessed for all subjects in terms of the frequency and percentage of reported adverse events (AEs) and serious adverse events (SAEs), which were collected from enrollment until the end of the study. The severities of events were determined by the investigator as mild to moderate if the event was transient and associated with no or some limitation in normal daily activity, or as severe if the event prevented the subject from performing normal daily activity. The relationship of the study treatment to an AE was determined by the investigator as not related, possibly related, or probably related.
Statistics
Approximately 252 healthy subjects aged 18 to 64 years were to be enrolled to achieve a minimum of 228 evaluable subjects (assuming a drop-out rate of 10%) to assess the primary immunogenicity objective. Overall, the study was powered at 86%, with 93% power for each of the two hepatitis antigens. The immunogenicity of a hepatitis A and/or B vaccine when coadministered with MenACWY-CRM was considered non-inferior to administration of a hepatitis A and/or B vaccine alone if, for each of the hepatitis antigens, the lower limit (LL) of the two-sided 95% confidence interval (CI) for the group ratio of GMCs (HepA/B + MenACWY-CRM to HepA/B) was greater than 0.5 as measured on day 29 (for previously vaccinated subjects) or day 57 (for previously unvaccinated subjects). For analyses involving GMTs and GMCs, the antibody titers/concentrations were logarithmically transformed (log 10 ). Titers/concentrations below the limit of detection were set to half that limit for the purpose of analysis. The GMTs/GMCs, GMC ratios, and the associated two-sided 95% CIs were derived using an analysis of covariance (ANCOVA) model with the vaccine group, center, and age included. The Clopper-Pearson method was used to calculate the two-sided 95% CIs for the percentage of subjects with anti-HAV antibody concentrations ≥20 mIU/mL and the percentage of subjects with anti-HBsAg antibody concentrations ≥10 mIU/mL, as well as for the percentage of subjects with seroresponse against meningococcal serogroups A, C, W-135, and Y within each vaccine group. All statistical analyses were performed by Novartis Vaccines using SAS ® version 9.1 (SAS Institute, Cary, NC, USA).
The primary immunogenicity analyses were conducted on the per protocol set (PPS), which included 156 subjects (HepA/B group, n = 78; HepA/B + Men ACWY-CRM group, n = 78).
Results

Enrollment, Study Flow, and Demographics
A total of 252 healthy adults aged 18 to 64 years were randomized to three groups with 84 subjects in each: HepA/B, HepA/B + MenACWY-CRM, and MenACWY-CRM. Of the enrolled subjects, 249 (99%) completed the study with one subject in each of the vaccine groups (n = 3; 1%) that withdrew from the study prematurely (Figure 1) . Reasons for the premature withdrawal were protocol deviation, as the subject met an exclusion criteria (n = 1); withdrawal of consent due to an AE (dizziness), which was judged as possibly related to study vaccination (n = 1); and death (n = 1), which was judged as not related to study vaccination. The demographics and baseline characteristics of the enrolled subjects were well balanced across the groups ( Table 1 ). The hepatitis A and/or B vaccination status of the subjects at the time of enrollment was similar across the three vaccine groups with 2% to 5%, 13% to 21%, and 19% to 30% of subjects previously vaccinated against hepatitis A only, hepatitis B only, or both hepatitis A and B, respectively.
Immunogenicity
Immunogenicity of Hepatitis A/B The primary immunogenicity objective was met as coadministration of a hepatitis A and/or B vaccine with
MenACWY-CRM was demonstrated to be non-inferior to administration of a hepatitis A and/or B vaccine alone. The LL of the 95% CI for the group ratio (HepA/B + MenACWY-CRM to HepA/B) for each of the anti-HAV and anti-HBsAg GMCs at 28 days following the last hepatitis A and/or B vaccination was greater than the pre-specified non-inferiority limit of 0.5 ( Table 2) .
At 28 days following the last hepatitis A and/or B vaccination, a majority of subjects in both groups had seroprotective antibody concentrations against HAV (HepA/B: 99%; HepA/B + MenACWY-CRM: 96%) or against HBsAg (HepA/B: 80%; HepA/B + MenACWY-CRM: 75%), with no evidence of any difference between the groups for each antigen (Figure 2A) . Within both the HepA/B and the HepA/B + MenACWY-CRM groups, robust responses against the hepatitis antigens were observed on day 29 in those individuals who received a booster dose of a hepatitis A and/or B vaccine on day 1 ( Figure 2B ). Comparatively, the anti-HAV and anti-HBsAg GMCs were one or two orders of magnitude lower, respectively, on day 57 among those individuals who received a primary vaccination series during the study. Notably, there were no differences between the HepA/B and HepA/B + MenACWY-CRM groups for anti-HAV or anti-HBsAg antibody GMCs within these subsets grouped according to similar hepatitis A/B vaccination history.
Immunogenicity of MenACWY-CRM The percentages of subjects who were seropositive (hSBA titers ≥4) for meningococcal serogroups A, C, W-135, and Y were similar between the HepA/B + MenACWY-CRM and MenACWY-CRM groups at baseline, with overall higher percentages of subjects being seropositive for serogroup W-135 (A: 16%-18%; C: 51%-53%; W-135: 79%-82%; and Y: 48%-49%). One month post-MenACWY-CRM vaccination, the percentage of subjects who achieved hSBA titers ≥8 against serogroups A, C, W-135, and Y were comparable between the HepA/B + MenACWY-CRM and MenACWY-CRM groups (A: 76% vs 67%; C: 87% vs 82%; W-135: 99% vs 96%; and Y: 94% vs 88%, respectively) ( Table 3 ). The GMTs and the percentage of subjects with seroresponse against serogroups A, C, W-135, and Y were also each comparable between the HepA/B + MenACWY-CRM and MenACWY-CRM groups at this time point (Table 3) .
Safety
All of the 252 enrolled subjects received at least one study vaccination and contributed to the safety analyses. The percentages of subjects who reported any AE were comparable between the HepA/B (43%) and HepA/B + MenACWY-CRM (39%) groups. Among the subjects who reported AEs, 53% (19/36) in the HepA/B group and 70% (23/33) in the HepA/B + MenACWY-CRM group reported an AE that was judged as at least possibly related to study vaccination by the investigator.
Overall, the most commonly reported AE by a preferred term in the HepA/B and HepA/B + MenACWY-CRM groups was headache (18 and 7%, respectively), followed by nasopharyngitis (7 and 11%, respectively) ( Table 4 ). All other reported AEs were reported by 7% of the subjects or fewer. Of the reported AEs, the most commonly reported ones by a preferred term in the HepA/B and HepA/B + MenACWY-CRM groups that were judged as at least possibly related to study vaccination by the investigator were headache (10 and 6%, respectively), nasopharyngitis (2 and 6%, respectively), and injection site pain (5 and 6%, respectively). Among all the groups, most of the reported AEs were mild to moderate in nature and all the AEs designated as at least possibly related to study vaccination were resolved before study termination. There were two reported SAEs (1%): one case of suspected renal cancer (HepA/B group) and one death (suicide; MenACWY-CRM group); both of these events were judged as not related to study vaccination.
Discussion
Observations of immune interference between concomitantly administered vaccines [31] [32] [33] illustrate the importance of evaluating the immunogenicity and safety of concomitant administration of any vaccine considered for simultaneous administration. For example, in a study evaluating concomitant administration versus sequential administration of a pneumococcal conjugate vaccine with a hepatitis B vaccine and a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate combination vaccine, reduced antibody responses to the hepatitis B antigen were observed following the concomitant administration series relative to the sequential administration series. 32 Nonetheless, national recommendations for concomitant administration of vaccines in routine immunization schedules are supported by the results of numerous clinical evaluations demonstrating that many vaccines can be coadministered without safety concerns and without consequences on immune responses to vaccine antigens. Of particular relevance to this study, previous evaluations of concomitant administration of a hepatitis A and/or B vaccine with polysaccharide vaccines, including a quadrivalent meningococcal polysaccharide tetanus toxoid conjugate vaccine, demonstrated that the evaluated vaccines can be coadministered without safety concerns and without comprising the immunogenicity of the vaccine antigens in the context of a standard hepatitis A/B immunization schedule. [34] [35] [36] The results of this study demonstrate that MenACWY-CRM can be coadministered with a hepatitis A and/or B vaccine, in the context of an accelerated hepatitis A and/or B immunization schedule, without safety concerns or interfering with immune responses to the hepatitis A and B antigens. In particular, the anti-HAV and anti-HBsAg GMCs were non-inferior when MenACWY-CRM was coadministered with a hepatitis A and/or B vaccine, as compared to administration of a hepatitis A and/or B vaccine alone. Moreover, seroprotection rates against hepatitis A and Table 4 Percentage of subjects with adverse events (AEs), by preferred term, judged as not related or at least possibly related to the study treatment by the study investigator (≥1%), by group B antigens were high and in the same range for the two groups. Within both groups, the GMCs for the hepatitis A and B antigens were much higher in the subjects who received a booster dose of a hepatitis A and/or B vaccine, as compared to those who received an accelerated primary series. These anamnestic responses are in accordance with those reported in other studies.
28,37
The results of this study also demonstrate that concomitant administration of MenACWY-CRM with the combined hepatitis A/B vaccine did not impair the antibody responses to meningococcal serogroups A, C, W-135, and Y, as compared to MenACWY-CRM administration alone. In particular, at least 67% of subjects exhibited hSBA titers ≥8 against serogroups A, C, W-135, and Y across both groups at 1 month post-MenACWY-CRM vaccination. The hSBA results observed in this study are comparable to those reported previously in adults following administration of a single dose of MenACWY-CRM alone. 38, 39 At baseline there were a greater percentage of subjects who were seropositive (hSBA titers ≥4) for serogroup W-135, as compared to the other serogroups. High baseline seropositivity against serogroup W-135 has been observed in other clinical studies 15, 18 and this trend may be attributed to region-specific meningococcal epidemiology, nasal colonization, or cross-reactivity of antibodies detected by the hSBA analyses. Importantly, while the overall seroresponse rates against serogroup W-135 were lower than the respective rates against the other serogroups, considering the high baseline seropositivity, the immunogenicity against serogroup W-135 was indeed robust, as at least 96% of subjects across both the HepA + MenACWY-CRM and MenACWY-CRM groups achieved hSBA titers ≥8 at 1 month post-vaccination.
Collectively, the results of this study demonstrate that MenACWY-CRM can be incorporated into the accelerated immunization schedule for hepatitis A and/or B vaccination without safety concerns and without interfering with immune responses to any tested vaccine antigens. These findings complement the results of previous studies demonstrating that MenACWY-CRM can be concomitantly administered with routine, as well as travel-indicated, vaccines without compromising immune responses against the vaccines or increasing safety concerns. [16] [17] [18] [19] In particular, in a recent study it was demonstrated that MenACWY-CRM can be concomitantly administered with travel-indicated vaccines for Japanese Encephalitis (JE) virus (inactivated, adsorbed JE vaccine; IXIARO ® , Valneva Austria GmbH, Vienna, Austria) and rabies virus [Purified Chick Embryo Cell rabies vaccine (PCEC; Rabipur ® , Novartis Vaccines)] without compromising antibody responses or increasing safety concerns of the individual vaccines. 19 In conclusion, the results of this study support the concomitant use of MenACWY-CRM with a hepatitis A and/or B vaccine, thereby providing an option for international travelers to reduce the number of office visits necessary to obtain the indicated pre-travel vaccinations and, in this way, may increase the likelihood of ensuring pre-travel immunity to both types of hepatitis and meningococcal serogroups A, C, W-135, and Y in these individuals.
